Alnylam Pharmaceuticals (NASDAQ:ALNY) Lifted to “Hold” at BidaskClub

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Tuesday, BidAskClub reports.

ALNY has been the subject of a number of other reports. BMO Capital Markets lifted their price target on shares of Alnylam Pharmaceuticals from $119.00 to $126.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. Cowen reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 6th. Morgan Stanley upgraded shares of Alnylam Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $122.00 price target for the company in a research note on Tuesday, March 5th. Cantor Fitzgerald reiterated a “buy” rating and issued a $135.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, April 9th. Finally, Zacks Investment Research lowered shares of Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $127.44.

Shares of ALNY stock opened at $70.00 on Tuesday. Alnylam Pharmaceuticals has a 52 week low of $60.27 and a 52 week high of $124.21. The company has a market capitalization of $7.53 billion, a PE ratio of -9.25 and a beta of 2.58. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.33 and a quick ratio of 9.12.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) EPS for the quarter, topping analysts’ consensus estimates of ($2.20) by $0.47. Alnylam Pharmaceuticals had a negative net margin of 929.51% and a negative return on equity of 55.33%. The firm had revenue of $33.29 million during the quarter, compared to analyst estimates of $21.60 million. During the same period in the previous year, the business posted ($1.22) earnings per share. The business’s revenue for the quarter was up 52.0% on a year-over-year basis. Equities research analysts anticipate that Alnylam Pharmaceuticals will post -8.48 EPS for the current fiscal year.

In related news, CEO John Maraganore sold 49,457 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $70.00, for a total transaction of $3,461,990.00. Following the completion of the sale, the chief executive officer now directly owns 239,450 shares in the company, valued at $16,761,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Philip A. Sharp sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $88.23, for a total transaction of $1,323,450.00. Following the sale, the director now owns 250,633 shares of the company’s stock, valued at $22,113,349.59. The disclosure for this sale can be found here. Insiders own 3.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in ALNY. ETF Managers Group LLC lifted its holdings in Alnylam Pharmaceuticals by 15.7% during the fourth quarter. ETF Managers Group LLC now owns 1,086 shares of the biopharmaceutical company’s stock valued at $79,000 after purchasing an additional 147 shares in the last quarter. US Bancorp DE lifted its holdings in Alnylam Pharmaceuticals by 66.2% during the first quarter. US Bancorp DE now owns 369 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 147 shares in the last quarter. Advisors Asset Management Inc. lifted its holdings in Alnylam Pharmaceuticals by 0.9% during the fourth quarter. Advisors Asset Management Inc. now owns 17,883 shares of the biopharmaceutical company’s stock valued at $1,304,000 after purchasing an additional 155 shares in the last quarter. M&T Bank Corp lifted its holdings in Alnylam Pharmaceuticals by 3.7% during the fourth quarter. M&T Bank Corp now owns 5,305 shares of the biopharmaceutical company’s stock valued at $387,000 after purchasing an additional 188 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ lifted its holdings in Alnylam Pharmaceuticals by 1.4% during the first quarter. Skandinaviska Enskilda Banken AB publ now owns 13,448 shares of the biopharmaceutical company’s stock valued at $1,257,000 after purchasing an additional 188 shares in the last quarter. Institutional investors own 89.78% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Recommended Story: What is the Fibonacci sequence?

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.